Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer xenografts

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Hagtvet, Eirik ^a,b   Røe, Kathrine ^a,b   Olsen, Dag R ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GADOTERATE MEGLUMINE; PIMONIDAZOLE; ANTINEOPLASTIC ANTIBIOTIC; CONTRAST MEDIUM; NITROIMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG CLEARANCE; DRUG FORMULATION; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE CANCER; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANOXIA; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; HUMAN; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; PROSTATE TUMOR; THEORETICAL MODEL; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; ANOXIA; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CONTRAST MEDIA; DOXORUBICIN; HUMANS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, THEORETICAL; NEOPLASM TRANSPLANTATION; NITROIMIDAZOLES; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 80053516109     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-135     Document Type: Article

References (42)

1. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93:266-276. 10.1093/jnci/93.4.266, 11181773.
2. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001, 28:29-35.
3. Marignol L, Coffey M, Lawler M, Hollywood D. Hypoxia in prostate cancer: a powerful shield against tumour destruction?. Cancer Treat Rev 2008, 34:313-327. 10.1016/j.ctrv.2008.01.006, 18334284.
4. Rudolfsson SH, Bergh A. Hypoxia drives prostate tumour progression and impairs the effectiveness of therapy, but can also promote cell death and serve as a therapeutic target. Expert Opin Ther Targets 2009, 13:219-225. 10.1517/14728220802626249, 19236239.
5. Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, Riddick AC. The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int 2010, 105:8-13.
6. Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007, 25:4066-4074. 10.1200/JCO.2007.12.7878, 17827455.
7. Wouters BG, Weppler SA, Koritzinsky M, Landuyt W, Nuyts S, Theys J, Chiu RK, Lambin P. Hypoxia as a target for combined modality treatments. Eur J Cancer 2002, 38:240-257. 10.1016/S0959-8049(01)00361-6, 11803141.
8. Bentzen SM, Harari PM, Bernier J. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol 2007, 4:172-180. 10.1038/ncponc0744, 17327857.
9. Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm--general principles. Nat Clin Pract Oncol 2007, 4:86-100. 10.1038/ncponc0714, 17259930.
10. Bellamy AS, Hill BT. Interactions between clinically effective antitumor drugs and radiation in experimental systems. Biochim Biophys Acta 1984, 738:125-166.
11. Bonner JA, Lawrence TS. Doxorubicin decreases the repair of radiation-induced DNA damage. Int J Radiat Biol 1990, 57:55-64. 10.1080/09553009014550341, 1967294.
12. Byfield JE, Lynch M, Kulhanian F, Chan PY. Cellular effects of combined adriamycin and x-irradiation in human tumor cells. Int J Cancer 1977, 19:194-204. 10.1002/ijc.2910190209, 838520.
13. Watring WG, Byfield JE, Lagasse LD, Lee YD, Juillard G, Jacobs M, Smith ML. Combination Adriamycin and radiation therapy in gynecologic cancers. Gynecol Oncol 1974, 2:518-526. 10.1016/0090-8258(74)90062-6, 4463153.
14. Durand RE. Adriamycin: a possible indirect radiosensitizer of hypoxic tumor cells. Radiology 1976, 119:217-222.
15. Batist G. Cardiac safety of liposomal anthracyclines. Cardiovasc Toxicol 2007, 7:72-74. 10.1007/s12012-007-0014-4, 17652807.
16. Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA. Cardiac safety of liposomal anthracyclines. Semin Oncol 2004, 31:161-181.
17. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284. 10.1016/S0168-3659(99)00248-5, 10699287.
18. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003, 42:419-436. 10.2165/00003088-200342050-00002, 12739982.
19. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Vile RG, Uster PS, Peters AM, Stewart JS. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin Cancer Res 2000, 6:4939-4949.
20. Koukourakis MI, Koukouraki S, Giatromanolaki A, Kakolyris S, Georgoulias V, Velidaki A, Archimandritis S, Karkavitsas NN. High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas--rationale for combination with radiotherapy. Acta Oncol 2000, 39:207-211. 10.1080/028418600430789, 10859012.
21. Davies CL, Lundstrom LM, Frengen J, Eikenes L, Bruland SOS, Kaalhus O, Hjelstuen MH, Brekken C. Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts. Cancer Res 2004, 64:547-553. 10.1158/0008-5472.CAN-03-0576, 14744768.
22. Koukourakis MI, Koukouraki S, Giatromanolaki A, Archimandritis SC, Skarlatos J, Beroukas K, Bizakis JG, Retalis G, Karkavitsas N, Helidonis ES. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol 1999, 17:3512-3521.
23. Petrioli R, Fiaschi AI, Francini E, Pascucci A, Francini G. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer. Cancer Treat Rev 2008, 34:710-718. 10.1016/j.ctrv.2008.05.004, 18620815.
24. Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, Resnick MI, Bodner DR, Jacobberger JW, Delmoro CM, Giaconia JM, Pretlow TP. Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst 1993, 85:394-398. 10.1093/jnci/85.5.394, 8433392.
25. Favier J, Lapointe S, Maliba R, Sirois MG. HIF2 alpha reduces growth rate but promotes angiogenesis in a mouse model of neuroblastoma. BMC Cancer 2007, 7:139. 10.1186/1471-2407-7-139, 1950713, 17655754.
26. Roe K, Seierstad T, Kristian A, Mikalsen LT, Maelandsmo GM, van der Kogel AJ, Ree AH, Olsen DR. Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions. Neoplasia 2010, 12:818-825. 2950331, 20927320.
27. Seierstad T, Roe K, Hovik B. Construction of a modified capacitive overlap MR coil for imaging of small animals and objects in a clinical whole-body scanner. Phys Med Biol 2007, 52:N513-N522. 10.1088/0031-9155/52/22/N02, 17975281.
28. Brix G, Semmler W, Port R, Schad LR, Layer G, Lorenz WJ. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 1991, 15:621-628. 10.1097/00004728-199107000-00018, 2061479.
29. Markwardt CB. Non-Linear Least Squares Fitting in IDL with MPFIT. proc Astronomical Data Analysis Software and Systems XVIII, Quebec, Canada, ASP Conference Series 2008, 411:251-254.
30. Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 2002, 10:539-548. 10.1080/1061186021000072447, 12683721.
31. Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A, Siegal T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Advanced Drug Delivery Reviews 1997, 24:337-344.
32. Harrington KJ, Rowlinson-Busza G, Uster PS, Vile RG, Peters AM, Stewart JS. Single-fraction irradiation has no effect on uptake of radiolabeled pegylated liposomes in a tumor xenograft model. Int J Radiat Oncol Biol Phys 2001, 49:1141-1148. 10.1016/S0360-3016(00)01444-9, 11240257.
33. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Vile RG, Peters AM, Stewart JS. The effect of irradiation on the biodistribution of radiolabeled pegylated liposomes. Int J Radiat Oncol Biol Phys 2001, 50:809-820. 10.1016/S0360-3016(01)01508-5, 11395251.
34. Durand RE, LePard NE. Modulation of tumor hypoxia by conventional chemotherapeutic agents. Int J Radiat Oncol Biol Phys 1994, 29:481-486. 10.1016/0360-3016(94)90442-1, 8005803.
35. Durand RE, LePard NE. Tumour blood flow influences combined radiation and doxorubicin treatments. Radiother Oncol 1997, 42:171-179. 10.1016/S0167-8140(96)01878-6, 9106927.
36. Verreault M, Strutt D, Masin D, Anantha M, Yung A, Kozlowski P, Waterhouse D, Bally MB, Yapp DT. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C), doxorubicin (Caelyx(R)) or vincristine. BMC Cancer 2011, 11:124. 10.1186/1471-2407-11-124, 3080346, 21477311.
37. Loncaster JA, Carrington BM, Sykes JR, Jones AP, Todd SM, Cooper R, Buckley DL, Davidson SE, Logue JP, Hunter RD, West CML. Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2002, 54:759-767. 10.1016/S0360-3016(02)02972-3, 12377328.
38. Saitoh J, Sakurai H, Suzuki Y, Muramatsu H, Ishikawa H, Kitamoto Y, Akimoto T, Hasegawa M, Mitsuhashi N, Nakano T. Correlations between in vivo tumor weight, oxygen pressure, 31P NMR spectroscopy, hypoxic microenvironment marking by beta-D-iodinated azomycin galactopyranoside (beta-D-IAZGP), and radiation sensitivity. Int J Radiat Oncol Biol Phys 2002, 54:903-909. 10.1016/S0360-3016(02)03013-4, 12377344.
39. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008, 49:129S-148S. 10.2967/jnumed.107.045914, 18523070.
40. Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT. Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol 2007, 8:63-74. 10.1016/S1470-2045(06)71012-9, 17196512.
41. Bussink J, Kaanders JH, van der Graaf WT, Oyen WJ. PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat Rev Clin Oncol 2011, 8:233-242. 10.1038/nrclinonc.2010.218, 21263464.
42. Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med 2009, 9:442-458. 10.2174/156652409788167087, 2752413, 19519402.